Thalassemia Treatment Market

Thalassemia Treatment Market (Treatment Type: Blood Transfusion, Chelation Therapy, Bone Marrow Transplantation, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Thalassemia Treatment Market Outlook 2031

  • The industry was valued at US$ 791.8 Mn in 2022
  • It is expected to increase at a CAGR of 7.3% from 2023 to 2031 and reach US$ 1.5 Bn by the end of 2031

Analyst Viewpoint

Growth in prevalence of thalassemia and R&D of new drugs for thalassemia treatment are driving the global thalassemia treatment market size. Various drugs for the treatment of thalassemia are in the pipeline. The majority of them are undergoing trials between Phase I and III.

Stem cell therapy is gaining traction for the treatment of thalassemia, especially for severe cases. Gene-edited cell therapy is also gaining popularity for the treatment of transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older.

Players in the thalassemia treatment market landscape are broadening their focus toward the treatment of alpha-thalassemia and beta-thalassemia. They are developing advanced thalassemia treatment strategies to expand their product portfolio.

Market Introduction

Thalassemia is one of the inherited blood disorders in which the body produces an inadequate quantity of hemoglobin. Blood transfusion solutions and chelation therapy are among the common treatments.

Chelation therapy makes use of drugs, such as deferasirox, for the treatment of chronic iron overloads that occur during frequent blood transfusions amongst non-transfusion-dependent thalassemia patients. They are administered subcutaneously or intravenously with slow infusion to purify the blood.

High treatment costs may compel the population in under-developed economies to give a second thought about resorting to thalassemia treatment. This factor may restrain the thalassemia treatment market development.

Growth in Prevalence of Thalassemia Propelling Market Progress

According to Boston Children’s Hospital, nearly 300 million individuals across the globe suffer from thalassemia trait. These individuals are at a higher risk of begetting children with thalassemia. The hospital further states that more than 100 thousand people are diagnosed with transfusion-dependent thalassemia.

Fetal hemoglobin inducers are recommended, such that decitabine and hydroxyurea can be successfully induced to elevate levels of fetal hemoglobin. Rise in need to reduce the number of thalassemia-infected patients (to prevent children from getting affected) is prompting extensive research pertaining to thalassemia treatment.

This, in turn, is augmenting the thalassemia treatment market demand. Various studies are focusing on devising erythropoiesis-stimulating agents to treat millions of adults contracting thalassemia due to kidney failure.

Rise in R&D of New Drugs for Thalassemia Treatment Fueling Thalassemia Treatment Market Revenue

Beta-thalassemia is prevalent in the Middle East, Mediterranean, South Asia, Africa, and India. It is conventionally managed through red blood cell transfusions at periodic intervals, usually every two to four weeks, followed by chelation therapy with deferoxamine (Novartis; Desferal) or deferasirox for removing excess iron from the bloodstream.

Patients, without these two courses of action, are likely to experience symptoms such as liver and cardiac ailments or chronic fatigue.

Emerging treatments like gene therapy aim to address the genetic mutations causing thalassemia. Gene therapy for thalassemia is still under research and development. Stem cell therapy, particularly hematopoietic stem cell transplantation (HSCT), is one of the primary and potentially curative treatments for thalassemia, especially for severe cases.

In 2019, the U.S. FDA approved luspatrcept-aamt (Reblozyl) for the treatment of thalassemia. Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia.

R&D of stem cell-based gene therapies is driving the thalassemia treatment market share. In 2019, Vifor Pharma reported positive phase-I trial results for its oral ferroportin inhibitor. In all treated trial participants, the ferroportin inhibitor was well tolerated with mild to moderate side effects that were transient and self-limiting.

Regional Outlook

According to the latest thalassemia treatment market forecast, North America is expected to hold largest share from 2023 to 2031. The region accounted for major share in 2022. Rise in awareness regarding thalassemia coupled with governments rendering support to gene therapy is fueling the market dynamics of the region.

The thalassemia treatment market growth in Europe and Asia Pacific can be ascribed to high demand for gene therapy for thalassemia treatment and surge in investment in healthcare infrastructure.

Increase in awareness regarding thalassemia is also boosting the market statistics in these regions. Healthcare experts state that marriages amongst cousins are likely to cause thalassemia in the progeny, especially in Asia Pacific.

Analysis of Key Players

Key players are engaging in extensive R&D activities to expand their product portfolio. Bluebird Bio, Inc., Merck & Co., Inc., Novartis AG, Celgene Corporation, Takeda Pharmaceutical Company Limited, Incyte Corporation, Sanofi, Bellicum Pharmaceuticals, and GSK plc are some of the key players in the thalassemia treatment industry.

Each of these companies has been profiled in the thalassemia treatment market report based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Key Developments

  • In January 2024, CRISPR Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older
  • In November 2023, The Medicines and Healthcare Regulatory Agency in the U.K. approved Casgevy for patients with sickle cell disease and thalassemia who are 12 years old and over

Thalassemia Treatment Market Snapshot

Attribute Detail
Market Size in 2022 US$ 791.8 Mn
Market Forecast (Value) in 2031 US$ 1.5 Bn
Growth Rate (CAGR) 7.3%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Mn/Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Treatment Type
    • Blood Transfusion
    • Chelation Therapy
    • Bone Marrow Transplantation
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Bluebird Bio, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Celgene Corporation
  • Takeda Pharmaceuticals Company Limited
  • Incyte Corporation
  • Sanofi
  • Bellicum Pharmaceuticals
  • GSK plc
  • Others
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global thalassemia treatment market in 2022?

It was valued at US$ 791.8 Mn in 2022

How is the thalassemia treatment business expected to grow during the forecast period?

It is projected to grow at a CAGR of 7.3% from 2023 to 2031

What are the key factors driving the demand for thalassemia treatment?

Growth in prevalence of thalassemia and R&D of new drugs for thalassemia treatment

Which thalassemia treatment type held the largest share in 2022?

The chelation therapy segment accounted for the largest share in 2022

Which region dominated the global thalassemia treatment landscape in 2022?

North America was the dominant region in thalassemia treatment market in 2022

Who are the key thalassemia treatment product manufacturers?

Bluebird Bio, Inc., Merck & Co., Inc., Novartis AG, Celgene Corporation, Takeda Pharmaceutical Company Limited, Incyte Corporation, Sanofi, Bellicum Pharmaceuticals, and GSK plc

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Thalassemia Treatment Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution/Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Thalassemia Treatment Market Analysis and Forecast, 2017–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Thalassemia Treatment Market Analysis and Forecast, by Treatment Type

        6.1. Introduction & Definition

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Treatment Type, 2017–2031

            6.3.1. Blood Transfusion

            6.3.2. Chelation Therapy

            6.3.3. Bone Marrow Transplantation

            6.3.4. Others

        6.4. Market Attractiveness Analysis, by Treatment Type

    7. Global Thalassemia Treatment Market Analysis and Forecast, by Region

        7.1. Key Findings

        7.2. Market Value Forecast, by Region, 2017–2031

            7.2.1. North America

            7.2.2. Europe

            7.2.3. Asia Pacific

            7.2.4. Latin America

            7.2.5. Middle East & Africa

        7.3. Market Attractiveness Analysis, by Region

    8. North America Thalassemia Treatment Market Analysis and Forecast

        8.1. Introduction

        8.2. Key Findings

        8.3. Market Value Forecast, by Treatment Type, 2017–2031

            8.3.1. Blood Transfusion

            8.3.2. Chelation Therapy

            8.3.3. Bone Marrow Transplantation

            8.3.4. Others

        8.4. Market Value Forecast, by Country, 2017–2031

            8.4.1. U.S.

            8.4.2. Canada

        8.5. Market Attractiveness Analysis

            8.5.1. By Treatment Type

            8.5.2. By Country

    9. Europe Thalassemia Treatment Market Analysis and Forecast

        9.1. Introduction

        9.2. Key Findings

        9.3. Market Value Forecast, by Treatment Type, 2017–2031

            9.3.1. Blood Transfusion

            9.3.2. Chelation Therapy

            9.3.3. Bone Marrow Transplantation

            9.3.4. Others

        9.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            9.4.1. Germany

            9.4.2. U.K.

            9.4.3. France

            9.4.4. Italy

            9.4.5. Spain

            9.4.6. Rest of Europe

        9.5. Market Attractiveness Analysis

            9.5.1. By Treatment Type

            9.5.2. By Country/Sub-region

    10. Asia Pacific Thalassemia Treatment Market Analysis and Forecast

        10.1. Introduction

        10.2. Key Findings

        10.3. Market Value Forecast, by Treatment Type, 2017–2031

            10.3.1. Blood Transfusion

            10.3.2. Chelation Therapy

            10.3.3. Bone Marrow Transplantation

            10.3.4. Others

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. China

            10.4.2. Japan

            10.4.3. India

            10.4.4. Australia & New Zealand

            10.4.5. Rest of Asia Pacific

        10.5. Market Attractiveness Analysis

            10.5.1. By Treatment Type

            10.5.2. By Country/Sub-region

    11. Latin America Thalassemia Treatment Market Analysis and Forecast

        11.1. Introduction

        11.2. Key Findings

        11.3. Market Value Forecast, by Treatment Type, 2017–2031

            11.3.1. Blood Transfusion

            11.3.2. Chelation Therapy

            11.3.3. Bone Marrow Transplantation

            11.3.4. Others

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. Brazil

            11.4.2. Mexico

            11.4.3. Rest of Latin America

        11.5. Market Attractiveness Analysis

            11.5.1. By Treatment Type

            11.5.2. By Country/Sub-region

    12. Middle East & Africa Thalassemia Treatment Market Analysis and Forecast

        12.1. Introduction

        12.2. Key Findings

        12.3. Market Value Forecast, by Treatment Type, 2017–2031

            12.3.1. Blood Transfusion

            12.3.2. Chelation Therapy

            12.3.3. Bone Marrow Transplantation

            12.3.4. Others

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. GCC Countries

            12.4.2. South Africa

            12.4.3. Rest of Middle East & Africa

        12.5. Market Attractiveness Analysis

            12.5.1. By Treatment Type

            12.5.2. By Country/Sub-region

    13. Competition Landscape

        13.1. Market Player - Competitive Matrix (by Tier and Size of Companies)

        13.2. Market Share Analysis, by Company (2022)

        13.3. Company Profiles

            13.3.1. Bluebird Bio, Inc.

                13.3.1.1. Company Overview

                13.3.1.2. Product Portfolio

                13.3.1.3. SWOT Analysis

                13.3.1.4. Financial Overview

                13.3.1.5. Strategic Overview

            13.3.2. Merck & Co., Inc.

                13.3.2.1. Company Overview

                13.3.2.2. Product Portfolio

                13.3.2.3. SWOT Analysis

                13.3.2.4. Financial Overview

                13.3.2.5. Strategic Overview

            13.3.3. Novartis AG

                13.3.3.1. Company Overview

                13.3.3.2. Product Portfolio

                13.3.3.3. SWOT Analysis

                13.3.3.4. Financial Overview

                13.3.3.5. Strategic Overview

            13.3.4. Celgene Corporation

                13.3.4.1. Company Overview

                13.3.4.2. Product Portfolio

                13.3.4.3. SWOT Analysis

                13.3.4.4. Financial Overview

                13.3.4.5. Strategic Overview

            13.3.5. Takeda Pharmaceuticals Company Limited

                13.3.5.1. Company Overview

                13.3.5.2. Product Portfolio

                13.3.5.3. SWOT Analysis

                13.3.5.4. Financial Overview

                13.3.5.5. Strategic Overview

            13.3.6. Incyte Corporation

                13.3.6.1. Company Overview

                13.3.6.2. Product Portfolio

                13.3.6.3. SWOT Analysis

                13.3.6.4. Financial Overview

                13.3.6.5. Strategic Overview

            13.3.7. Sanofi

                13.3.7.1. Company Overview

                13.3.7.2. Product Portfolio

                13.3.7.3. SWOT Analysis

                13.3.7.4. Financial Overview

                13.3.7.5. Strategic Overview

            13.3.8. Bellicum Pharmaceuticals

                13.3.8.1. Company Overview

                13.3.8.2. Product Portfolio

                13.3.8.3. SWOT Analysis

                13.3.8.4. Financial Overview

                13.3.8.5. Strategic Overview

            13.3.9. GSK plc

                13.3.9.1. Company Overview

                13.3.9.2. Product Portfolio

                13.3.9.3. SWOT Analysis

                13.3.9.4. Financial Overview

                13.3.9.5. Strategic Overview

    List of Tables

    Table 01: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 02: Global Thalassemia Treatment Market Size (US$ Mn) Forecast, by Region, 2017–2031

    Table 03: North America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country, 2017–2031

    Table 04: North America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 05: Europe Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 06: Europe Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 07: Asia Pacific Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 08: Asia Pacific Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 09: Latin America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Latin America Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031

    Table 11: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 12: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2017–2031

    List of Figures

    Figure 01: Global Thalassemia Treatment Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031

    Figure 02: Global Thalassemia Treatment Market Revenue (US$ Mn), by Treatment Type, 2022

    Figure 03: Global Thalassemia Treatment Market Value Share, by Treatment Type, 2022

    Figure 04: Global Thalassemia Treatment Market Value Share, by Region, 2022

    Figure 05: Global Thalassemia Treatment Market Value (US$ Mn) Forecast, 2023–2031

    Figure 06: Global Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031

    Figure 07: Global Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031

    Figure 08: Global Thalassemia Treatment Market Value Share Analysis, by Region, 2022–2031

    Figure 09: Global Thalassemia Treatment Market Attractiveness Analysis, by Region, 2023–2031

    Figure 10: North America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 11: North America Thalassemia Treatment Market Attractiveness Analysis, by Country, 2023–2031

    Figure 12: North America Thalassemia Treatment Market Value Share Analysis, by Country, 2022–2031

    Figure 13: North America Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031

    Figure 14: North America Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031

    Figure 15: Europe Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 16: Europe Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 17: Europe Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 18: Europe Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031

    Figure 19: Europe Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031

    Figure 20: Asia Pacific Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 21: Asia Pacific Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 22: Asia Pacific Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 23: Asia Pacific Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031

    Figure 24: Asia Pacific Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031

    Figure 25: Latin America Thalassemia Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 26: Latin America Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 27: Latin America Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 28: Latin America Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031

    Figure 29: Latin America Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031

    Figure 30: Middle East & Africa Thalassemia Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

    Figure 31: Middle East & Africa Thalassemia Treatment Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 32: Middle East & Africa Thalassemia Treatment Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 33: Middle East & Africa Thalassemia Treatment Market Value Share Analysis, by Treatment Type, 2022–2031

    Figure 34: Middle East & Africa Thalassemia Treatment Market Attractiveness Analysis, by Treatment Type, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved